Phase II Study to Investigate Concurrent Lapatinib and Radiotherapy in Locally Advanced or Locally Recurrent Breast Cancer and the Impact on Breast Cancer Stem Cells
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2017
Price : $35 *
At a glance
- Drugs Lapatinib (Primary)
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- 17 Nov 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov
- 04 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jul 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.